UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments

Advanced materials (Weinheim), 2019-03, Vol.31 (10), p.e1806899-n/a

2019

Volltextzugriff (PDF)

A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells

Leukemia, 2021-06, Vol.35 (6), p.1586-1596

2021

Volltextzugriff (PDF)

CD133, Selectively Targeting the Root of Cancer

Toxins, 2016-05, Vol.8 (6), p.165

2016

Volltextzugriff (PDF)

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

Blood, 2014-05, Vol.123 (19), p.3016-3026

2014

Volltextzugriff (PDF)

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies

Clinical cancer research, 2015-03, Vol.21 (6), p.1267-1272

2015

Volltextzugriff (PDF)

Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies

Toxins, 2018-01, Vol.10 (1), p.32

2018

Volltextzugriff (PDF)

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS

Blood advances, 2018-06, Vol.2 (12), p.1459-1469

2018

Volltextzugriff (PDF)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors

Biomolecules (Basel, Switzerland), 2020-06, Vol.10 (6), p.956

2020

Volltextzugriff (PDF)

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

Frontiers in immunology, 2023-02, Vol.14, p.1060905-1060905

2023

Volltextzugriff (PDF)

Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma - A pilot study

PloS one, 2017-02, Vol.12 (2), p.e0172651-e0172651

2017

Volltextzugriff (PDF)

Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic

Journal of the American Chemical Society, 2010-12, Vol.132 (48), p.17247-17257

2010

Volltextzugriff (PDF)

Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA

Immuno, 2023-06, Vol.3 (2), p.237-249

2023

Volltextzugriff (PDF)

Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy

Seminars in immunology, 2017-06, Vol.31, p.64-75

2017

Volltextzugriff (PDF)

Immunotoxins Targeting B cell Malignancy-Progress and Problems With Immunogenicity

Biomedicines, 2018-12, Vol.7 (1), p.1

2018

Volltextzugriff (PDF)

Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors

International journal of cancer, 2013-10, Vol.133 (8), p.1936-1944

2013

Volltextzugriff (PDF)

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

Clinical cancer research, 2016-07, Vol.22 (14), p.3440-3450

2016

Volltextzugriff (PDF)

Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings

Molecular cancer therapeutics, 2023-03, Vol.22 (3), p.371-380

2023

Volltextzugriff (PDF)

Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells

Methods in molecular biology (Clifton, N.J.), 2016-01, Vol.1441, p.333

2016

Volltextzugriff (PDF)

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells

Blood advances, 2018-07, Vol.2 (13), p.1580-1584

2018

Volltextzugriff (PDF)

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma

Targeted oncology, 2014-09, Vol.9 (3), p.239-249

2014

Volltextzugriff (PDF)

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma

Clinical cancer research, 2009-10, Vol.15 (19), p.6137-6147

2009

Volltextzugriff (PDF)

Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker

Molecular therapy, 2016-08, Vol.24 (7), p.1312-1322

2016

Volltextzugriff (PDF)

A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma

Clinical cancer research, 2005-05, Vol.11 (10), p.3879-3888

2005

Volltextzugriff (PDF)

Self‐Assembly of Antibodies by Chemical Induction

Angewandte Chemie International Edition, 2008-12, Vol.47 (52), p.10179-10182

2008

Volltextzugriff (PDF)

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16×33 Bispecific Killer Cell Engager and ADAM17 Inhibition

Clinical cancer research, 2013-07, Vol.19 (14), p.3844-3855

2013

Volltextzugriff (PDF)

1 – 25 von 205

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

ThemaMice, Inbred C57bl

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(170)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments

A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells

CD133, Selectively Targeting the Root of Cancer

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies

Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma - A pilot study

Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic

Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA

Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy

Immunotoxins Targeting B cell Malignancy-Progress and Problems With Immunogenicity

Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings

Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma

Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker

A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma

Self‐Assembly of Antibodies by Chemical Induction

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16×33 Bispecific Killer Cell Engager and ADAM17 Inhibition

Aktive Filter

Suchergebnisse filtern